Ocera Therapeutics, Inc. (OCRX) Rating Increased to Buy at Zacks Investment Research
Zacks Investment Research upgraded shares of Ocera Therapeutics, Inc. (NASDAQ:OCRX) from a hold rating to a buy rating in a report issued on Saturday morning. The firm currently has $1.00 price objective on the biopharmaceutical company’s stock.
According to Zacks, “Ocera Therapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of proprietary compounds to treat acute and chronic orphan liver diseases. Ocera Therapeutics, Inc., formerly known as Tranzyme, Inc., is based in San Diego, California. “
OCRX has been the subject of a number of other research reports. HC Wainwright restated a buy rating and issued a $4.00 price objective on shares of Ocera Therapeutics in a research report on Wednesday, May 10th. Aegis restated a buy rating and issued a $3.00 price objective on shares of Ocera Therapeutics in a research report on Wednesday, May 24th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of $3.80.
Shares of Ocera Therapeutics (NASDAQ:OCRX) opened at 0.94 on Friday. Ocera Therapeutics has a 12 month low of $0.52 and a 12 month high of $3.15. The stock’s market cap is $24.92 million. The firm has a 50-day moving average price of $1.11 and a 200-day moving average price of $1.10.
Ocera Therapeutics (NASDAQ:OCRX) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.24) by $0.01. Ocera Therapeutics had a negative net margin of 4,416.26% and a negative return on equity of 175.02%. Equities analysts forecast that Ocera Therapeutics will post ($1.20) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Ocera Therapeutics, Inc. (OCRX) Rating Increased to Buy at Zacks Investment Research” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/ocera-therapeutics-inc-ocrx-rating-increased-to-buy-at-zacks-investment-research/1530694.html.
A number of hedge funds and other institutional investors have recently modified their holdings of OCRX. Virtu KCG Holdings LLC boosted its position in shares of Ocera Therapeutics by 194.6% in the second quarter. Virtu KCG Holdings LLC now owns 213,531 shares of the biopharmaceutical company’s stock worth $248,000 after buying an additional 141,040 shares during the period. Hikari Power Ltd boosted its position in shares of Ocera Therapeutics by 50.6% in the second quarter. Hikari Power Ltd now owns 376,596 shares of the biopharmaceutical company’s stock worth $437,000 after buying an additional 126,596 shares during the period. Renaissance Technologies LLC boosted its position in shares of Ocera Therapeutics by 17.9% in the fourth quarter. Renaissance Technologies LLC now owns 219,100 shares of the biopharmaceutical company’s stock worth $460,000 after buying an additional 33,300 shares during the period. Finally, Perceptive Advisors LLC bought a new position in shares of Ocera Therapeutics during the first quarter worth about $2,817,000. 20.25% of the stock is owned by institutional investors.
Ocera Therapeutics Company Profile
Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ocera Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.